First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices

Retrospective Cohort ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

First Line Treatment ◽

Platinum Doublet

PCN183 A Cost-Effectiveness Analysis of Nivolumab plus Ipilimumab plus Two Cycles of Platinum Doublet-Chemotherapy Versus Platinum Doublet Chemotherapy in the First-Line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer in Canada

Value in Health ◽

10.1016/j.jval.2021.04.274 ◽

2021 ◽

Vol 24 ◽

pp. S53

Author(s):

K.C. Young ◽

H. Sandhu ◽

A. Lee ◽

K. Lakhdari ◽

J. Maervoet ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis ◽

Doublet Chemotherapy ◽

First Line Treatment ◽

Platinum Doublet

A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903

ESMO Open ◽

10.1016/j.esmoop.2021.100115 ◽

2021 ◽

Vol 6 (3) ◽

pp. 100115

Author(s):

K. Ito ◽

M. Morise ◽

K. Wakuda ◽

O. Hataji ◽

T. Shimokawaji ◽

...

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Multicenter Cohort Study ◽

Multicenter Cohort ◽

Egfr Mutated ◽

Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)

Investigational New Drugs ◽

10.1007/s10637-019-00843-y ◽

2019 ◽

Vol 37 (6) ◽

pp. 1266-1273 ◽

Cited By ~ 9

Author(s):

Motohiro Tamiya ◽

Akihiro Tamiya ◽

Kazutaka Hosoya ◽

Yoshihiko Taniguchi ◽

Toshihide Yokoyama ◽

...

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Retrospective Cohort ◽

Small Cell ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy

HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2019.7467 ◽

2020 ◽

Vol 18 (3.5) ◽

pp. HSR20-108

Author(s):

Ashley Tabah ◽

David Huggar ◽

Ronda Copher ◽

Marc Tian ◽

Ali McBride

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Retrospective Cohort ◽

Treatment Patterns ◽

Small Cell ◽

Small Cell Lung ◽

First Line

The efficacy of bevacizumab in addition to platinum-based chemotherapy for first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer (NSCLC): Final results of AVALANCHE, an observational cohort study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e19123 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e19123-e19123

Author(s):

Edina Tolnay ◽

Veronika Sarosi ◽

Erzsebet Juhasz ◽

Zsuzsanna Sztancsik ◽

Gyorgy Losonczy ◽

...

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Small Cell ◽

Observational Cohort Study ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Platinum Based Chemotherapy ◽

Observational Cohort ◽

Hospital Costs Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in China: A Retrospective Cohort Study

Value in Health ◽

10.1016/j.jval.2014.08.101 ◽

2014 ◽

Vol 17 (7) ◽

pp. A734

Author(s):

J Chen ◽

S Wu ◽

C Hu ◽

Y Yang ◽

N Rajan ◽

...

Keyword(s):

Lung Cancer ◽

Cohort Study ◽

Small Cell Lung Cancer ◽

Retrospective Cohort ◽

Hospital Costs ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Line Setting

Efficacy of pemetrexed plus platinum doublet chemotherapy as first-line treatment for advanced nonsquamous non-small-cell-lung cancer: a systematic review and meta-analysis

OncoTargets and Therapy ◽

10.2147/ott.s96160 ◽

2016 ◽

pp. 1471 ◽

Cited By ~ 3

Author(s):

Yi-Ming Ni ◽

Huai-Qing Xiao ◽

Rong-Hua Tian ◽

Zhi-Hao Zhang ◽

Kai-Qi Du

Keyword(s):

Lung Cancer ◽

Systematic Review ◽

Meta Analysis ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

First Line Treatment ◽

Platinum Doublet

Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride

Case Medical Research ◽

10.31525/ct1-nct03890055 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Clinical Study ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

First Line Treatment with Erlotinib Plus Bevacizumab or with Erlotinib Alone in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations (NEJ026): An Open-Label, Randomized, Multicenter, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271416 ◽

2018 ◽

Author(s):

Haruhiro Saito ◽

Tatsuro Fukuhara ◽

Naoki Furuya ◽

Kana Watanabe ◽

Shunichi Sugawara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Multicenter Phase ◽